PubRank

G C de Gast

Author PubWeight™ 80.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Functional studies on lymphocytes in adult human bone marrow. II. Isolated surface IgM-positive cells. J Immunol 1979 1.70
2 Passive-active immunization in infants of hepatitis Be antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization. Am J Dis Child 1993 1.61
3 Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000 1.60
4 Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997 1.44
5 Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 1994 1.39
6 Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002 1.22
7 Specific lymphocyte stimulation by purified, heat-inactivated hepatitis-B antigen. Br Med J 1973 1.16
8 Lymphocyte 5'-nucleotidase in primary hypogammaglobulinaemia and cord blood. Clin Exp Immunol 1980 1.14
9 Early detection of active cytomegalovirus (CMV) infection after heart and kidney transplantation by testing for immediate early antigenemia and influence of cellular immunity on the occurrence of CMV infection. J Clin Microbiol 1990 1.14
10 The human immune response to alpha-haemocyanin of Helix pomatia. Acta Med Scand 1973 1.11
11 Class-specific antibody titres (ELISA) against the primary immunogen Helix pomatia haemocyanin (HPH) in man. Clin Exp Immunol 1978 1.10
12 Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE. Immunology 1990 1.08
13 Is cytomegalovirus infection a major cause of T cell alterations after (autologous) bone-marrow transplantation? Lancet 1984 1.07
14 Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol 1989 1.04
15 Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen. Pediatrics 1989 1.03
16 Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 1997 1.03
17 Detection of cytomegalovirus (CMV) in granulocytes by polymerase chain reaction compared with the CMV antigen test. J Clin Microbiol 1992 1.01
18 Associated expression of CD1 antigen and Fc receptor for IgE on epidermal Langerhans cells from patients with atopic dermatitis. Clin Exp Immunol 1988 1.00
19 Immunoglobulin and complement inclusions in peripheral blood polymorphonuclear leucocytes of patients with bronchial carcinoma. Thorax 1977 0.99
20 Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol 1998 0.99
21 The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol 2002 0.99
22 T lymphocyte repopulation and differentiation after bone marrow transplantation. Early shifts in the ratio between T4+ and T8+ T lymphocytes correlate with the occurrence of acute graft-versus-host disease. Blood 1984 0.98
23 Functional studies on lymphocytes in adult human bone marrow. I. Immunoglobulin production in vitro after fractionation on a sucrose gradient and T/non-T cell separation. J Immunol 1979 0.95
24 Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol 1999 0.94
25 Herpes-virus immunity and acute graft-versus-host disease. Lancet 1987 0.93
26 Delay in platelet recovery after bone marrow transplantation: impact of cytomegalovirus infection. Blood 1985 0.93
27 Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial). Thorax 1978 0.91
28 A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 1991 0.90
29 Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003 0.90
30 Acute humoral rejection after heart transplantation. Transplantation 1988 0.89
31 Phenotypic study of CD4+ and CD8+ lymphocyte subsets in relation to cytomegalovirus carrier status and its correlate with pokeweed mitogen-induced B lymphocyte differentiation. Clin Exp Immunol 1989 0.87
32 PHA-induced cytotoxicity of human lymphocytes against adherent hela cells. J Immunol Methods 1978 0.87
33 Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization. Cancer 1975 0.87
34 Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination. Hepatogastroenterology 1988 0.87
35 A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation. Blood 1990 0.86
36 Recovery of T cell subsets after autologous bone marrow transplantation is mainly due to proliferation of mature T cells in the graft. Blood 1985 0.85
37 Induction of IgM production by pokeweed mitogen and interleukin-2: different responses by human peripheral blood cells and tonsil cells. Clin Immunol Immunopathol 1986 0.85
38 Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer 2003 0.85
39 Syngeneic leukocytes together with suramin failed to improve immunodeficiency in a case of transfusion-associated AIDS after syngeneic bone marrow transplantation. Blood 1988 0.84
40 Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplant 1992 0.83
41 Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. Bone Marrow Transplant 1993 0.83
42 Cellular immunocompetence in asymptomatic paraproteinaemia. Acta Med Scand 1977 0.82
43 Hepatocyte growth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells. Leukemia 1998 0.82
44 Influence of cytomegalovirus infection on the recovery of humoral immunity after autologous bone marrow transplantation. Exp Hematol 1987 0.81
45 Cytomegalovirus infection causes delayed platelet recovery after bone marrow transplantation. Blood 1991 0.81
46 Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 2005 0.81
47 Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood 1995 0.81
48 The multifactorial etiology of graft-versus-host disease. Immunol Today 1987 0.80
49 Suppression of DNA synthesis by con A-activated human lymphocytes: role of monocytes in con A-induced suppression. Clin Exp Immunol 1980 0.80
50 B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease. Br J Cancer 1997 0.80
51 Immune response in asymptomatic paraproteinemia. I. Primary and secondary antibody response to Helix pomatia hemocyanin. Scand J Immunol 1976 0.80
52 Serology versus PCR-SSP in typing for HLA-DR and HLA-DQ: a practical evaluation. Tissue Antigens 1995 0.80
53 Lysosomal enzymes in normal and leukemic B lymphocytes. Clin Chim Acta 1982 0.80
54 Glycolytic enzymes of an erythroleukemic cell line, K562, before and after hemoglobin induction. Exp Hematol 1983 0.80
55 Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant 1989 0.80
56 Immunotherapeutic potential of bispecific antibodies. Immunol Today 1997 0.80
57 HNK-1+ cells in non-Hodgkin's lymphoma: lack of relation with transferrin receptor expression on malignant cells. Br J Cancer 1985 0.80
58 Intensive cytoreductive therapy followed by autologous bone marrow transplantation for patients with hematologic malignancies or solid tumors. Cancer 1987 0.80
59 Impaired lymphocyte function and neutrophil damage during the first hours of hemodialysis. Clin Nephrol 1977 0.79
60 Surface immunoglobulin restriction in B-non Hodgkin's lymphomas in cell suspension and on frozen tissue sections. Scand J Haematol 1985 0.79
61 Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19. Scand J Immunol 1997 0.79
62 Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol Immunother 1996 0.79
63 The primary immune response of patients with different stages of squamous-cell bronchial carcinoma. Thorax 1978 0.79
64 Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994 0.79
65 Human tonsil B lymphocyte function. II. Pokeweed mitogen-induced plasma cell differentiation of B cell subpopulations expressing multiple heavy chain isotypes on their surface. J Immunol 1984 0.79
66 Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. J Hepatol 1997 0.79
67 Antibodies to platelets in patients with anti-phospholipid antibodies. Blood 1991 0.78
68 Isozyme distribution of hexokinase, phosphofructokinase and pyruvate kinase in lymphocytes from patients with chronic lymphocytic leukemia. Clin Chim Acta 1982 0.78
69 Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992 0.78
70 Human B7-1 is more efficient than B7-2 in providing co-stimulation for alloantigen-specific T cells. Eur J Immunol 1996 0.78
71 Cytomegalovirus immunity in allogeneic marrow grafting. Transplantation 1985 0.78
72 Epstein-Barr virus infection abrogates the stimulatory capacity of B cells to a major histocompatibility complex class-II-restricted proliferative T-cell clone. Hum Immunol 1995 0.78
73 Expression of restricted immunoglobulin isotypes in plasmacellular hyperplasia after allogeneic bone marrow transplantation. Scand J Immunol 1987 0.78
74 Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP. J Clin Oncol 1992 0.77
75 Monotypic immunoglobulin E plasma cells in an allogeneic bone marrow transplant recipient. Histopathology 1986 0.77
76 Reduction and repopulation of T-lymphocytes after cytoreductive therapy with or without autologous bone marrow rescue. Exp Hematol 1986 0.77
77 Intensive cytotoxic therapy followed by autologous bone marrow transplantation for non-Hodgkin's lymphoma of high-grade malignancy. Blood 1985 0.77
78 Influence of graft-versus-host disease prophylaxis on early T-lymphocyte regeneration following allogeneic bone marrow transplantation. Br J Haematol 1986 0.77
79 Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 1993 0.77
80 Functional expression of minor histocompatibility antigens on human peripheral blood dendritic cells and epidermal Langerhans cells. Transpl Immunol 1996 0.77
81 Myotonic dystrophy associated with hereditary motor and sensory neuropathy. Brain 1986 0.77
82 Comparison of various in vitro assays for efficacy screening of immunotoxins. Leuk Res 1995 0.77
83 Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 1987 0.76
84 Detection improvement of cytomegalovirus antigen in human peripheral blood using monoclonal antibodies and automated reading of cell preparations. Eur J Clin Invest 1995 0.76
85 Immune reactivity of women on hormonal contraceptives: dinitrochlorobenzene sensitization test and skin reactivity to irritants. Contraception 1979 0.76
86 GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy. Eur J Cancer 1999 0.76
87 Neonatal neutropenia due to maternal autoantibodies against neutrophils. Br Med J (Clin Res Ed) 1983 0.76
88 Discordance of Epstein-Barr Virus (EBV) specific humoral and cellular immunity in patients with malignant lymphomas: elevated antibody titres and lowered in vitro lymphocyte reactivity. Clin Exp Immunol 1978 0.76
89 HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice. Br J Cancer 1999 0.76
90 Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma. Clin Exp Immunol 2010 0.75
91 Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2003 0.75
92 Effects of interleukin-2 on hepatitis B vaccination in uraemic patients. Lancet 1994 0.75
93 Letter: Tests for drug allergy. Lancet 1974 0.75
94 Reduction and repopulation of recipient T4+ and T8+ T-lymphocytes in allogeneic bone marrow transplantation. Exp Hematol 1986 0.75
95 Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis. Transpl Int 1993 0.75
96 Toward preclinical studies with anti-CD86 immunotoxin. Transplant Proc 1999 0.75
97 Primary cytomegalovirus infection and its prevention after autologous bone marrow transplantation. Transplantation 1985 0.75
98 Immune reactivity of women on hormonal contraceptives. Phytohemagglutinin and concanavalin-A induced lymphocyte response. Contraception 1980 0.75
99 Depletion of T cells from bone marrow grafts with soybean agglutinin and sheep red blood cells for prevention of graft-versus-host disease. Haematol Blood Transfus 1987 0.75
100 Determination of helper T-cell precursor frequencies against non-haemopoietic cells: comparison of co-stimulation provided by anti-CD28 antibody versus the cellular ligand B7-1. Br J Haematol 2000 0.75
101 [Hepatitis B vaccine: accused but exonerated]. Ned Tijdschr Geneeskd 1983 0.75
102 Enzymological studies in chronic lymphocytic leukemia. Leuk Res 1983 0.75
103 Prevention of primary T-cell responses by immunotoxins directed against CD80 and CD86. Transplant Proc 1997 0.75
104 Phytohemagglutin-induced lymphocyte cytotoxicity in hemodialysis patients with hepatitis B virus infection. Hepatogastroenterology 1981 0.75
105 Detection of plasmacytoma of the nasal cavity by immunoelectrophoresis of nasal washing fluid. J Laryngol Otol 1976 0.75
106 Immunological aspects of melanomas [proceedings]. Ophthalmologica 1977 0.75
107 Peanut agglutinin (PNA) binding as a marker for immature human B lymphocytes. Is bone marrow not the complete bursa-equivalent? Adv Exp Med Biol 1982 0.75
108 [Difficulties in the diagnosis and therapy of patients with tumors of the lymphatic system]. Ned Tijdschr Geneeskd 1986 0.75
109 Acute humoral rejection in a heart transplant recipient. Transplant Proc 1989 0.75
110 Marrow donor immunity to herpes simplex virus: association with acute graft-versus-host disease. Exp Hematol 1987 0.75
111 [Malignant disorders of the lymphatic system]. Ned Tijdschr Geneeskd 1986 0.75
112 Primary human keratinocytes as targets in predicting acute graft-versus-host disease following HLA-identical bone marrow transplantation. Br J Haematol 2000 0.75
113 Detection of keratinocyte-specific helper T-lymphocyte precursor cells for prediction of acute graft-versus-host-disease. Transplant Proc 1997 0.75
114 Differentiation between irreversible and reversible rejection in renal transplant patients by monitoring of phytohemagglutinin-induced cytotoxicity. Transplantation 1980 0.75
115 [Secondary immunodeficiencies]. Ned Tijdschr Geneeskd 1986 0.75
116 Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study. Haematol Blood Transfus 1990 0.75
117 Dendritic cells induce HLA-DP-specific T-cell proliferation between MLR-negative siblings. Immunogenetics 1995 0.75
118 Lymphocyte-transformation test in drug allergy. Lancet 1977 0.75
119 [Increased susceptibility for infection in malignant diseases of the lymphatic system]. Ned Tijdschr Geneeskd 1986 0.75
120 Transplantation of marrow from donors other than genotypically HLA-identical siblings. Neth J Med 1987 0.75
121 [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells]. Ned Tijdschr Geneeskd 1986 0.75
122 High immune responsiveness in a family with multiple paraproteinaemia and autoimmune thyroid disease. Acta Med Scand 1980 0.75
123 Clinical application of the polymerase chain reaction in the detection of HLA-B27 alleles. Clin Exp Rheumatol 1996 0.75
124 Analysis of dendritic-cell-induced primary T-cell responses between HLA genotypically identical individuals. Hum Immunol 1995 0.75
125 [High dose cytotoxic agents followed by autologous bone marrow transplantation; treatment results in 25 patients with various malignancies]. Ned Tijdschr Geneeskd 1985 0.75
126 Hexokinase, phosphofructokinase and pyruvate kinase isoenzymes in lymphocyte subpopulations. Clin Chim Acta 1984 0.75
127 Cellular immunity to vaccinations and herpesvirus infections after bone marrow transplantation. Transplantation 1986 0.75
128 Rapid detection of CMV reactivation after BMT by CMV-IEA expression in granulocytes. Bone Marrow Transplant 1991 0.75
129 Primary T-cell responses induced by B7-transfected keratinocytes. Immunol Today 1996 0.75
130 Human keratinocytes expressing HLA class II induce short-term anergy toward alloantigens. Transplant Proc 1997 0.75
131 The effect of immunotoxins directed against CD80 and CD86 on primary T-cell alloresponses. Tissue Antigens 1998 0.75
132 Specific interferon-gamma producing CD4+ and CD8+ T cells after autologous EBV-B stimulation: the necessity of restimulation. Scand J Immunol 1995 0.75
133 Purine metabolizing enzyme activities in lymphoblastic leukemia. Adv Exp Med Biol 1984 0.75
134 [Hepatitis B vaccination of hospital personnel]. Ned Tijdschr Geneeskd 1984 0.75
135 [Combined passive and active immunization of infants of HbsAg-positive mothers]. Ned Tijdschr Geneeskd 1985 0.75
136 Patch tests in drug eruptions. Contact Dermatitis 1975 0.75
137 Bone marrow transplantation with a fixed low number of T-cells in the graft. Haematol Blood Transfus 1990 0.75
138 [Are there perspectives with transplantation of autologous bone marrow for patients with acute leukemia?]. Ned Tijdschr Geneeskd 1983 0.75
139 Immune function during ageing in man: relation between serological abnormalities and cellular immune status. Eur J Clin Invest 1983 0.75
140 Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains. Ther Immunol 1994 0.75
141 Cytotoxic T-cell capacity after autologous bone marrow transplantation. Exp Hematol 1985 0.75
142 Parallel tubular structures in lymphocytes. II. Correlation with cellular immunity and cytomegalovirus and Epstein-Barr virus antibodies in Hodgkin's disease. Acta Haematol 1975 0.75
143 Class- and subclass-specific antibody response to hemocyanin in nonmalignant paraproteinemia. J Lab Clin Med 1979 0.75
144 Immunological responsiveness in idiopathic and drug-induced panmyelopathy: discrepancy between sensitization with DNCB and haemocyanin. Br J Haematol 1974 0.75
145 Metastatic renal-cell carcinoma developing in two recipients of renal grafts derived from the same donor. Nephrol Dial Transplant 1995 0.75
146 Targeting of cytotoxic T cells against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its primary target. J Immunol 1997 0.75